So is this it in a nut shell:
- we have bought a CAR-T for $12m
- That CAR-T has been greenlighted to go straight to a registrational trial
- Because of its orphan status that trial is way quicker and easier
- The trial will cost $20m
If I am correct in my understanding then those are all the good things about this deal. Indeed, it seems a good deal period. The bad aspect is the CAP Raise. Totally unnecessary and certainly should not have been done at a discount. Could have been funded from existing cash.
I don't agree that we should have bought this company given they hold other tech we don't need and the license price was about as cheap as it gets. I would hope there is still more announcements to come before we trade again. I hope they just consolidate now and dual list on the nasdaq to get it over with. I think that would help lift the SP.
- Forums
- ASX - By Stock
- IMU
- Ann: Imugene Licenses Allogeneic CD19 CAR T Cell Therapy
Ann: Imugene Licenses Allogeneic CD19 CAR T Cell Therapy, page-85
-
- There are more pages in this discussion • 422 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add IMU (ASX) to my watchlist
(20min delay)
|
|||||
Last
5.1¢ |
Change
0.003(5.21%) |
Mkt cap ! $360.7M |
Open | High | Low | Value | Volume |
4.9¢ | 5.1¢ | 4.8¢ | $1.491M | 30.29M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
20 | 1528182 | 5.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
5.1¢ | 1110837 | 21 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
19 | 1448182 | 0.050 |
25 | 8391458 | 0.049 |
29 | 6586411 | 0.048 |
36 | 2494346 | 0.047 |
38 | 3415215 | 0.046 |
Price($) | Vol. | No. |
---|---|---|
0.051 | 1110837 | 21 |
0.052 | 1088659 | 17 |
0.053 | 2437306 | 13 |
0.054 | 1101565 | 10 |
0.055 | 3251521 | 14 |
Last trade - 12.54pm 18/09/2024 (20 minute delay) ? |
Featured News
IMU (ASX) Chart |